• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    5/12/23 4:51:18 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email
    SC 13D/A 1 l63466793.htm SCHEDULE 13D/A, AMENDMENT #5


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

    Alphatec Holdings, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    02081G102
    (CUSIP Number)
     
    Jeffrey Wade
    c/o LS Power Development, LLC
    1700 Broadway, 35th Floor
    New York, New York 10019
    212-547-2914
     
    With a copy to:
    Adam M. Turteltaub
    Willkie Farr & Gallagher LLP
    787 Seventh Avenue
    New York, New York 10019
    212-728-8129
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    May 10, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this statement on Schedule 13D (this “Schedule 13D”), and is filing this Schedule 13D because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No. 02081G102
    Page 2 of 7 Pages



     
    SCHEDULE 13D
       
    1
    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     
    L-5 Healthcare Partners, LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
     
    3
    SEC USE ONLY
     
     
    4
    SOURCE OF FUNDS
    WC
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7
    SOLE VOTING POWER
    0
     
    8
    SHARED VOTING POWER
    11,081,538
     
    9
    SOLE DISPOSITIVE POWER
    0
     
    10
    SHARED DISPOSITIVE POWER
    11,081,538
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    11,081,538
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
    ☐
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.35% (1)
     
    14
    TYPE OF REPORTING PERSON
    OO
     
     
    (1)  Calculation is based upon 118,496,526 shares of Common Stock outstanding as reported in the Issuer’s Form 10-Q filed on April 27, 2023.



    CUSIP No. 02081G102
    Page 3 of 7 Pages


     
    SCHEDULE 13D
    1
    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     
    Paul Segal
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS
    OO
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
    ☐
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7
    SOLE VOTING POWER
    171,329
    8
    SHARED VOTING POWER
    11,081,538 (1)
    9
    SOLE DISPOSITIVE POWER
    171,329
    10
    SHARED DISPOSITIVE POWER
    11,081,538 (1)
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    11,252,867
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
     ☐
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    9.50% (2)
    14
    TYPE OF REPORTING PERSON
    IN
    (1)  Represents 11,081,538 shares of Common Stock held by L-5 Healthcare Partners, LLC.
    (2)  Calculation is based upon 118,496,526 shares of Common Stock outstanding as reported in the Issuer’s Form 10-Q filed on April 27, 2023.
     



    CUSIP No. 02081G102
    Page 4 of 7 Pages
    The Schedule 13D filed with the Securities and Exchange Commission on March 16, 2018 (as previously amended, the "Schedule 13D") by (i) L-5 Healthcare Partners, LLC, a Delaware limited liability company (“L-5”), and (ii) Paul Segal, an individual with United States citizenship (collectively, the “Reporting Persons”), with respect to the common stock, par value $0.0001 per share (the “Common Stock”), of Alphatec Holdings, Inc., a Delaware corporation (the “Issuer”), is hereby amended to furnish the additional information set forth herein.  All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
    Item 5. Interest in Securities of the Issuer.
    Item 5 of the Schedule 13D is hereby amended and restated as follows:
    (a) and (b) The information contained on the cover pages to this Schedule 13D and Item 3 is incorporated herein by reference
    The aggregate percentage of Common Stock reported owned by each person named herein is based upon 118,496,526 shares of Common Stock outstanding as of April 27, 2023, which is the total number of shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2023.
    L-5 directly holds 11,081,538 shares of Common Stock reported in this Schedule 13D. As a result of his relationship with L-5, Paul Segal may be deemed the beneficial owner of all such shares of Common Stock. Mr. Segal, however, disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest therein. Mr. Segal also directly holds 171,329 shares of Common Stock reported in this Schedule 13D.
    (c) The transactions effected by the Reporting Persons during the past 60 days are set forth on Schedule 1 attached hereto.
    (d) Not applicable.
    (e) Not applicable.



    CUSIP No. 02081G102
    Page 5 of 7 Pages
    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Schedule 13D is true, complete and correct.

    Dated:  May 12, 2023


     
    L-5 HEALTHCARE PARTNERS, LLC
       
       
     
    By:
    /s/ Paul Segal                                                  
     
    Name:
    Paul Segal
     
    Title:
    President
       
       
       
       
     
    /s/ Paul Segal                                  
     
    Paul Segal




    CUSIP No. 02081G102
    Page 5 of 7 Pages
    Schedule I
    1.
    The following transactions were effected by L-5 during the past 60 days:
    Date
    Security
    Amount of Shares Sold
    Approximate Price ($) per Share
    May 10, 2023
    Common Stock
    1,675,445
    $14.8750
    May 10, 2023
    Common Stock
    91
    $15.1900
    May 10, 2023
    Common Stock
    91
    $15.2000
    May 10, 2023
    Common Stock
    91
    $15.2200
    May 10, 2023
    Common Stock
    350
    $15.2300
    May 10, 2023
    Common Stock
    91
    $15.2400
    May 10, 2023
    Common Stock
    14
    $15.2500
    May 10, 2023
    Common Stock
    182
    $15.2700
    May 10, 2023
    Common Stock
    173
    $15.3000
    May 10, 2023
    Common Stock
    182
    $15.3050
    May 10, 2023
    Common Stock
    182
    $15.3100
    May 10, 2023
    Common Stock
    364
    $15.3200
    May 10, 2023
    Common Stock
    273
    $15.3300
    May 10, 2023
    Common Stock
    91
    $15.3350
    May 10, 2023
    Common Stock
    455
    $15.3400
    May 10, 2023
    Common Stock
    282
    $15.3500
    May 10, 2023
    Common Stock
    273
    $15.3600
    May 10, 2023
    Common Stock
    91
    $15.3671
    May 10, 2023
    Common Stock
    91
    $15.3700
    May 10, 2023
    Common Stock
    91
    $15.3800
    May 10, 2023
    Common Stock
    683
    $15.3900
    May 10, 2023
    Common Stock
    484
    $15.4000
    May 10, 2023
    Common Stock
    27
    $15.4050
    May 10, 2023
    Common Stock
    146
    $15.4100
    May 10, 2023
    Common Stock
    364
    $15.4150
    May 10, 2023
    Common Stock
    662
    $15.4200
    May 10, 2023
    Common Stock
    182
    $15.4250
    May 10, 2023
    Common Stock
    91
    $15.4275
    May 10, 2023
    Common Stock
    567
    $15.4300
    May 10, 2023
    Common Stock
    364
    $15.4350
    May 10, 2023
    Common Stock
    588
    $15.4400
    May 10, 2023
    Common Stock
    91
    $15.4424
    May 10, 2023
    Common Stock
    182
    $15.4425
    May 10, 2023
    Common Stock
    291
    $15.4450
    May 10, 2023
    Common Stock
    1,557
    $15.4500
    May 10, 2023
    Common Stock
    91
    $15.4525
    May 10, 2023
    Common Stock
    1,073
    $15.4600
    May 10, 2023
    Common Stock
    91
    $15.4625
    May 10, 2023
    Common Stock
    273
    $15.4650
    May 10, 2023
    Common Stock
    91
    $15.4675
    May 10, 2023
    Common Stock
    1,275
    $15.4700
    May 10, 2023
    Common Stock
    182
    $15.4725
    May 10, 2023
    Common Stock
    364
    $15.4750
    May 10, 2023
    Common Stock
    1,305
    $15.4800
    May 10, 2023
    Common Stock
    91
    $15.4850
    May 10, 2023
    Common Stock
    1,185
    $15.4900
    May 10, 2023
    Common Stock
    304
    $15.4950
    May 10, 2023
    Common Stock
    1,092
    $15.5000
    May 10, 2023
    Common Stock
    364
    $15.5050
    May 10, 2023
    Common Stock
    1,365
    $15.5100
    May 10, 2023
    Common Stock
    637
    $15.5150
    May 10, 2023
    Common Stock
    940
    $15.5200
    May 10, 2023
    Common Stock
    91
    $15.5250
    May 10, 2023
    Common Stock
    547
    $15.5400
    May 10, 2023
    Common Stock
    91
    $15.5450
    May 10, 2023
    Common Stock
    272
    $15.5500
    May 10, 2023
    Common Stock
    91
    $15.5550
    May 10, 2023
    Common Stock
    91
    $15.5650
    May 10, 2023
    Common Stock
    364
    $15.5800
    May 10, 2023
    Common Stock
    91
    $15.5900
    May 10, 2023
    Common Stock
    455
    $15.6000
    May 10, 2023
    Common Stock
    637
    $15.6100
    May 10, 2023
    Common Stock
    455
    $15.6200
    May 10, 2023
    Common Stock
    91
    $15.6250
    May 10, 2023
    Common Stock
    91
    $15.6350
    May 10, 2023
    Common Stock
    182
    $15.6400
    May 10, 2023
    Common Stock
    182
    $15.6450
    May 10, 2023
    Common Stock
    91
    $15.6500
    May 10, 2023
    Common Stock
    182
    $15.6600
    May 10, 2023
    Common Stock
    91
    $15.6650
    All of the above transaction were effected on the open market.



    CUSIP No. 02081G102
    Page 7 of 7 Pages
    2.
    The following transactions were effected by Paul Segal during the past 60 days:
    Date
    Security
    Amount of Shares Sold
    Approximate Price ($) per Share
    May 10, 2023
    Common Stock
    165,070
    $14.8750
    May 10, 2023
    Common Stock
    9
    $15.1900
    May 10, 2023
    Common Stock
    9
    $15.2000
    May 10, 2023
    Common Stock
    9
    $15.2200
    May 10, 2023
    Common Stock
    35
    $15.2300
    May 10, 2023
    Common Stock
    9
    $15.2400
    May 10, 2023
    Common Stock
    1
    $15.2500
    May 10, 2023
    Common Stock
    18
    $15.2700
    May 10, 2023
    Common Stock
    17
    $15.3000
    May 10, 2023
    Common Stock
    18
    $15.3050
    May 10, 2023
    Common Stock
    18
    $15.3100
    May 10, 2023
    Common Stock
    36
    $15.3200
    May 10, 2023
    Common Stock
    27
    $15.3300
    May 10, 2023
    Common Stock
    9
    $15.3350
    May 10, 2023
    Common Stock
    45
    $15.3400
    May 10, 2023
    Common Stock
    28
    $15.3500
    May 10, 2023
    Common Stock
    27
    $15.3600
    May 10, 2023
    Common Stock
    9
    $15.3671
    May 10, 2023
    Common Stock
    9
    $15.3700
    May 10, 2023
    Common Stock
    9
    $15.3800
    May 10, 2023
    Common Stock
    67
    $15.3900
    May 10, 2023
    Common Stock
    48
    $15.4000
    May 10, 2023
    Common Stock
    3
    $15.4050
    May 10, 2023
    Common Stock
    15
    $15.4100
    May 10, 2023
    Common Stock
    36
    $15.4150
    May 10, 2023
    Common Stock
    65
    $15.4200
    May 10, 2023
    Common Stock
    18
    $15.4250
    May 10, 2023
    Common Stock
    9
    $15.4275
    May 10, 2023
    Common Stock
    56
    $15.4300
    May 10, 2023
    Common Stock
    36
    $15.4350
    May 10, 2023
    Common Stock
    58
    $15.4400
    May 10, 2023
    Common Stock
    9
    $15.4424
    May 10, 2023
    Common Stock
    18
    $15.4425
    May 10, 2023
    Common Stock
    29
    $15.4450
    May 10, 2023
    Common Stock
    154
    $15.4500
    May 10, 2023
    Common Stock
    9
    $15.4525
    May 10, 2023
    Common Stock
    106
    $15.4600
    May 10, 2023
    Common Stock
    9
    $15.4625
    May 10, 2023
    Common Stock
    27
    $15.4650
    May 10, 2023
    Common Stock
    9
    $15.4675
    May 10, 2023
    Common Stock
    125
    $15.4700
    May 10, 2023
    Common Stock
    18
    $15.4725
    May 10, 2023
    Common Stock
    36
    $15.4750
    May 10, 2023
    Common Stock
    128
    $15.4800
    May 10, 2023
    Common Stock
    9
    $15.4850
    May 10, 2023
    Common Stock
    117
    $15.4900
    May 10, 2023
    Common Stock
    30
    $15.4950
    May 10, 2023
    Common Stock
    108
    $15.5000
    May 10, 2023
    Common Stock
    36
    $15.5050
    May 10, 2023
    Common Stock
    135
    $15.5100
    May 10, 2023
    Common Stock
    63
    $15.5150
    May 10, 2023
    Common Stock
    93
    $15.5200
    May 10, 2023
    Common Stock
    9
    $15.5250
    May 10, 2023
    Common Stock
    54
    $15.5400
    May 10, 2023
    Common Stock
    9
    $15.5450
    May 10, 2023
    Common Stock
    27
    $15.5500
    May 10, 2023
    Common Stock
    9
    $15.5550
    May 10, 2023
    Common Stock
    9
    $15.5650
    May 10, 2023
    Common Stock
    36
    $15.5800
    May 10, 2023
    Common Stock
    9
    $15.5900
    May 10, 2023
    Common Stock
    45
    $15.6000
    May 10, 2023
    Common Stock
    63
    $15.6100
    May 10, 2023
    Common Stock
    45
    $15.6200
    May 10, 2023
    Common Stock
    9
    $15.6250
    May 10, 2023
    Common Stock
    9
    $15.6350
    May 10, 2023
    Common Stock
    18
    $15.6400
    May 10, 2023
    Common Stock
    18
    $15.6450
    May 10, 2023
    Common Stock
    9
    $15.6500
    May 10, 2023
    Common Stock
    18
    $15.6600
    May 10, 2023
    Common Stock
    9
    $15.6650
    All of the above transaction were effected on the open market.


    Get the next $ATEC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    10/12/2022$12.00Buy
    Jefferies
    9/12/2022$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:32:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:27:25 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Demski David M bought $283,500 worth of shares (50,000 units at $5.67), increasing direct ownership by 21% to 288,441 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/21/24 10:00:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on Alphatec with a new price target

      Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

      6/16/25 8:53:19 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec downgraded by Morgan Stanley

      Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight

      8/1/24 3:06:35 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Barclays initiated coverage on Alphatec with a new price target

      Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

      7/8/24 7:34:11 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Lish Scott sold $251,588 worth of shares (22,727 units at $11.07), decreasing direct ownership by 3% to 748,918 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/17/25 6:00:06 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Woods Ward W Jr was granted 15,131 shares, increasing direct ownership by 11% to 154,291 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:17 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Valentine Keith was granted 15,131 shares, increasing direct ownership by 18% to 97,271 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:16 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    SEC Filings

    See more
    • SEC Form S-8 filed by Alphatec Holdings Inc.

      S-8 - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:46:41 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:03:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Alphatec Holdings Inc.

      144 - Alphatec Holdings, Inc. (0001350653) (Subject)

      6/11/25 11:15:31 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • ATEC Reports First Quarter 2025 Financial Results and Raises Full-Year Guidance

      Surgical revenue grew 24%; total revenue grew 22% Full-year revenue and profitability guidance increased Successfully refinanced convertible debt to 2030 maturity Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2025, and recent corporate highlights. First Quarter 2025 Financial Results   Quarter Ended March 31, 2025 Total revenue $169 million GAAP gross margin 69% Non-GAAP gross margin 70% GAAP operating expenses $160 million Non-GAAP operating expenses $124 million GAAP net income /

      5/1/25 4:05:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC Launches PTP™ Corpectomy, The Next Evolution of Lateral Approach Surgery

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system. This milestone marks the continued evolution of ATEC's PTP surgical approach, expanding its capabilities to include deformity and corpectomy procedures for complex pathologies of the thoracolumbar spine. "PTP Corpectomy represents a significant step forward in ATEC's commitment to improving patient outcomes in the most complex spine surgeries," said Pat Miles, Chairman and Chief Executive Officer. "By integrating advanced surgical techniques within a fully proceduralized

      4/21/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

      Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

      4/4/24 9:05:00 AM ET
      $ATEC
      $SYK
      Medical/Dental Instruments
      Health Care
    • John Booth to Retire as CEO of Spineology Inc.

      Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the

      11/9/23 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Financials

    Live finance-specific insights

    See more
    • ATEC to Report First Quarter 2025 Financial Results on May 1, 2025

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2025 financial results on May 1, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducemen

      4/14/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Third Quarter Financial Results on October 30, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu

      10/7/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Second Quarter Financial Results on July 31, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2024 financial results on July 31, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.

      7/10/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      11/12/24 8:04:57 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      3/22/24 7:57:56 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      5/12/23 4:51:18 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care